Printer Friendly

ALLIANCE PHARMACEUTICAL ANNOUNCES COMMENCEMENT OF CLINICAL TRIAL

ALLIANCE PHARMACEUTICAL ANNOUNCES COMMENCEMENT OF CLINICAL TRIAL
    SAN DIEGO, July 1 /PRNewswire/ -- Alliance Pharmaceutical Corp. (NASDAQ: ALLP) announced today that it has commenced a Phase I clinical (human) trial in the United States for its Imagent(R)LN product.  ImagentLN is a perflubron-based emulsion developed for use in imaging lymph nodes with computed tomography (CT).
    Determining the involvement of lymph nodes in the spread of cancer can be important in selection of appropriate treatment. Currently, this involvement is determined by surgical methods such as biopsy.  ImagentLN is designed for subcutaneous (under the skin) or intramuscular injection, and thus could potentially offer the first non-surgical method to aid in evaluating the spread of certain cancers in lymph nodes.
    Alliance is a leader in the development of proprietary pharmaceutical products based upon perfluorocarbon and emulsion technologies.  The company's efforts focus on two primary areas: diagnostic contrast agents for use with major imaging modalities to aid in the early diagnosis of certain cancers and other pathological conditions; and oxygen carriers for use as a temporary red blood cell substitute and as adjunctive treatments of various cardiovascular, cancer and respiratory conditions.
    -0-                    7/1/92
    /CONTACT:  Stuart Gauld of Alliance Pharmaceutical, 619-558-4300/
    (ALLP) CO:  Alliance Pharmaceutical Corp. ST:  California IN:  MTC SU: AL-CH -- SD005 -- 5630 07/01/92 11:08 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1992
Words:217
Previous Article:MERRILL CORPORATION OPENS NEW JERSEY PRINTING FACILITY
Next Article:KIRKLAND GROUP AWARDED NEW LICENSE IN SOUTH WALES FOR COALBED METHANE EXPLORATION
Topics:


Related Articles
AGOURON PHARMACEUTICALS ANNOUNCES START OF HUMAN CLINICAL TRIALS FOR NEW ANTI-TUMOR AGENT
HYAL ANNOUNCES ITS FIRST PHASE III CLINICAL TRIAL FOR INJECTABLE, INTRAVENOUS PAIN PRODUCT ALL LEAD PRODUCTS NOW IN PHASE III
Alliance Pharmaceutical Corp. Announces Milestone Payment
Corvas Begins U.S. Clinical Trial with its Novel Anticoagulant, NAPc2
Somerset Pharmaceuticals Reports Results Of Clinical Trial In Major Depression
Epimmune Appoints Michael McClurg Vice President, Business Development.
Alliance Pharmaceutical Corp. and LEO Pharma A/S Modify Exclusivity Agreement Related to the Development and Marketing of Oxygent(tm) in Europe and...
GlaxoSmithKline and Pharmacopeia Enter Into Drug Discovery and Development Alliance.
GlaxoSmithKline and Pharmacopeia Enter Into Drug Discovery and Development Alliance.
Alliance Pharmaceutical Corp. Completes the Manufacture of Oxygent (TM) for Clinical Trials.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters